Jonathan Darrow

List of Publications by Year
in descending order

60 papers	1,547 citations	430874 18 h-index	315739 38 g-index
60 all docs	60 docs citations	60 times ranked	1488 citing authors

#	Article	IF	Citations
1	Two views of cancer medicines: Imagery versus evidence. Health Marketing Quarterly, 2023, 40, 141-152.	1.0	1
2	Expertsâ€™ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. Journal of General Internal Medicine, 2022, , 1.	2.6	1
3	New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence. Drug Safety, 2022, 45, 305-318.	3.2	7
4	Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes. Nature Biotechnology, 2022, 40, 167-169.	17.5	1
5	Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi Panel. Clinical Pharmacology and Therapeutics, 2022, 111, 1307-1314.	4.7	2
6	Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. BMJ Open, 2022, 12, e058279.	1.9	4
7	Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020. JAMA Network Open, 2022, 5, e2212454.	5.9	11
8	Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities. American Journal of Public Health, 2022, 112, 1110-1114.	2.7	0
9	An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19. Health Affairs, 2021, 40, 25-32.	5.2	27
10	Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding. Health Affairs, 2021, 40, 281-288.	5.2	5
11	Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines. Vaccine, 2021, 39, 2328-2330.	3.8	0
12	Changing FDA Approval Standards: Ethical Implications for Patient Consent. Journal of General Internal Medicine, 2021, 36, 3212-3214.	2.6	10
13	Integrating New Effectiveness Data Into US Food and Drug Administrationâ€“Approved Drug Labeling. JAMA Internal Medicine, 2021, 181, 897-898.	5.1	5
14	The timing of 30â€month stay expirations and generic entry: A cohort study of first generics, 2013â€“2020. Clinical and Translational Science, 2021, 14, 1917-1923.	3.1	5
15	Few new drugs deserve expedited regulatory treatment. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 685-688.	0.9	6
16	Government Pharmaceutical Development to Address High Prices: Challenges Ahead. Therapeutic Innovation and Regulatory Science, 2021, 55, 1103-1105.	1.6	2
17	Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed. Clinical Pharmacology and Therapeutics, 2021, 110, 1018-1024.	4.7	11
18	FDA Regulation and Approval of Medical Devices: 1976-2020. JAMA - Journal of the American Medical Association, 2021, 326, 420.	7.4	53

#	Article	IF	Citations
19	The Perils of Increasing Medicaid Rebates for Drugs With Accelerated Approval. JAMA Health Forum, 2021, 2, e213184.	2.2	1
20	Evidence Supporting the Value of Surgical Procedures: Can We Do Better?. American Surgeon, 2021, 87, 1352-1355.	0.8	0
21	Simplify drug labelling to show benefits clearly. Nature, 2021, 599, 181-181.	27.8	0
22	Efficacy and costs of spinal muscular atrophy drugs. Science Translational Medicine, 2020, 12, .	12.4	19
23	Understanding when real world data can be used to replicate a clinical trial: A crossâ€sectional study of medications approved in 2011. Pharmacoepidemiology and Drug Safety, 2020, 29, 1273-1278.	1.9	2
24	Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984â€“2018: an evaluation of Food and Drug Administration flexibilities. Lancet Infectious Diseases, The, 2020, 20, e159-e164.	9.1	3
25	Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clinical Pharmacology and Therapeutics, 2020, 108, 1308-1314.	4.7	7
26	FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA - Journal of the American Medical Association, 2020, 323, 164.	7.4	197
27	Incentivizing Antibiotic Development: Why Isnâ€™t the Generating Antibiotic Incentives Now (GAIN) Act Working?. Open Forum Infectious Diseases, 2020, 7, ofaa001.	0.9	19
28	Commentary: Expedited Regulatory Review of Low-Value Drugs. Healthcare Policy, 2020, 15, 35-40.	0.6	0
29	Patent term restoration for top-selling drugs in the United States. Drug Discovery Today, 2019, 24, 20-25.	6.4	18
30	The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Applied Health Economics and Health Policy, 2019, 17, 47-54.	2.1	10
31	Designing development programs for non-traditional antibacterial agents. Nature Communications, 2019, 10, 3416.	12.8	46
32	Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discovery Today, 2019, 24, 949-954.	6.4	133
33	Approximating Future Generic Entry for New Drugs. Journal of Law, Medicine and Ethics, 2019, 47, 177-182.	0.9	3
34	The <scp>US</scp> Biosimilar Market: Stunted Growth and Possible Reforms. Clinical Pharmacology and Therapeutics, 2019, 105, 92-100.	4.7	41
35	An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?. Nature Biotechnology, 2019, 37, 21-22.	17.5	4
36	The FDA Breakthrough-Drug Designation â€” Four Years of Experience. New England Journal of Medicine, 2018, 378, 1444-1453.	27.0	44

#	Article	IF	Citations
37	The Regulatory Accountability Act of 2017 â€" Implications for FDA Regulation and Public Health. New England Journal of Medicine, 2018, 378, 412-414.	27.0	2
38	Efficacy, Safety, and Regulatory Approval of Food and Drug Administrationâ€"Designated Breakthrough and Nonbreakthrough Cancer Medicines. Journal of Clinical Oncology, 2018, 36, 1805-1812.	1.6	72
39	Pharmaceutical Advertising in Medical Journals. Chest, 2018, 153, 9-11.	0.8	7
40	Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. Health Affairs, 2018, 37, 724-731.	5.2	27
41	A Method for Approximating Future Entry of Generic Drugs. Value in Health, 2018, 21, 1382-1389.	0.3	21
42	The FDAâ€™s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016. JAMA - Journal of the American Medical Association, 2017, 318, 2137.	7.4	62
43	Speed, Safety, and Industry Funding â€" From PDUFA I to PDUFA VI. New England Journal of Medicine, 2017, 377, 2278-2286.	27.0	31
44	Will inter partes review speed US generic drug entry?. Nature Biotechnology, 2017, 35, 1139-1141.	17.5	7
45	A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy. Journal of Law, Medicine and Ethics, 2017, 45, 692-697.	0.9	8
46	Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ, The, 2015, 351, h4633.	6.0	143
47	FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes. Clinical Pharmacology and Therapeutics, 2015, 97, 29-36.	4.7	36
48	Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 279-286.	27.0	125
49	Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 1473-1474.	27.0	3
50	A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges?. Food and Drug Law Journal, 2015, 70, 243-58, i.	0.4	5
51	Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?. Yale Journal of Health Policy, Law, and Ethics, 2015, 15, 293-347.	1.5	5
52	Drug Development and FDA Approval, 1938â€"2013. New England Journal of Medicine, 2014, 370, e39.	27.0	39
53	Existing FDA Pathways Have Potential To Ensure Early Access To, And Appropriate Use Of, Specialty Drugs. Health Affairs, 2014, 33, 1770-1778.	5.2	13
54	New FDA Breakthrough-Drug Category â€" Implications for Patients. New England Journal of Medicine, 2014, 370, 1252-1258.	27.0	102

#	Article	IF	Citations
55	New FDA Breakthrough-Drug Category â€" Implications for Patients. New England Journal of Medicine, 2014, 371, 87-90.	27.0	9
56	Regulation of Drugs for Early Alzheimer's Disease. New England Journal of Medicine, 2013, 369, 288-288.	27.0	7
57	Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. Journal of Law, Medicine and Ethics, 2013, 41, 590-600.	0.9	112
58	An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India. Health Matrix, 2013, 23, 425-57.	1.5	0
59	Recent Developments in Health Law. Journal of Law, Medicine and Ethics, 2011, 39, 291-300.	0.9	2
60	Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. Frontiers in Pharmacology, 0, 13, .	3.5	11